Background and objectives: Corticosteroids and cyclosporine A are frequently ineffective as first-line therapies in the treatment of pyoderma gangrenosum (PG) and associated with a number of adverse effects. The objective of the present study was to analyze the effectiveness and safety of biologics and intravenous immunoglobulins (IVIGs). Patients and methods: Retrospective, dual-center cohort study analyzing the treatment outcome in patients with PG who received biologics and IVIGs. Results: Fifty-two patients (mean age: 58.4 years) with 75 wound episodes (mean wound size: 53.2 cm²) were included in the study. Overall, 92.3 % of patients initially received corticosteroids (CSs; 48/52); 51.9 % cyclosporine A (CSA; 27/52). In 275 therapeutic attempts, complete remission or improvement were achieved in 63.6 % (21/33) of patients on infliximab; 57.1 % (16/28) on adalimumab; 71.4 % (5/7) on etanercept; 66.6 % (6/9) on ustekinumab and 66.7 % (10/15) of patients who were given IVIGs. 
Introduction
With a prevalence of 0.3-1.0/100,000, pyoderma gangrenosum (PG) is considered to be an orphan disease. Clinically, the condition is characterized by sudden onset of sterile pustules, predominantly on the lower legs, that spontaneously progress to exceedingly painful ulcers with raised, undermined borders and a necrotic base [1] [2] [3] . Roughly one-half of those affected have an underlying condition such as diabetes, chronic infl ammatory bowel disease, or a malignancy. However, the frequency (18-79 %) of these comorbidities reported in the literature varies greatly [ 2, [4] [5] [6] [7] [8] . A recent study also showed a close association with metabolic syndrome, with nearly all patients (94.8 %) exhibiting at least some features thereof [ 8 ] . Treatment of patients with PG includes antiinfl ammatory pharmacotherapy, treatment of underlying comorbidities, phase-adapted wound management, and appropriate pain management [ 9 ] . Based on data currently available, a randomized controlled trial from the UK and various case series in recent decades, corticosteroids (CSs) (0.5-1 mg/kg/d) and cyclosporine A (CSA) (5 mg/kg/d) are recommended as fi rst-line therapeutic agents [ 9, 10 ] , even though only CSs are approved for this indication. Complete remission rates of less than 46 % within six months and adverse effects in two out of three cases, as demonstrated by the 2015 STOP GAP study from the UK, underscore the need for effective and safe treatment alternatives [ 10 ] . Apart from CSs and CSA, other agents currently prescribed include conventional immunosuppressants such as azathioprine (AZA), mycophenolate mofetil (MMF), and methotrexate (MTX). The level of evidence associated with these agents is based exclusively on case reports and retrospective cohort analyses. A retrospective analysis of 121 individual disease courses suggested a higher rate of initial response with MMF (81 %) compared to AZA (68 %); however, AZA more frequently caused adverse effects (15 %) [ 11 ] . Given that treatment of PG is frequently challenging, regimens usually consist of a combination of CSs with some other agent. In the majority of cases, patients receive two or more different immunosuppressants until complete remission is achieved [ 11 ] .
Ever since biologics were fi rst introduced into clinical practice, there has been an increasing number of reports on the use of various antibodies for the treatment of PG, including tumor necrosis factor (TNF) α antagonists as well as anti-interleukin (IL) 1 and anti-IL-12/23 antibodies. These agents are given in light of the pathophysiologically signifi cant, increased cytokine release, which plays a key role in the infl ammatory process associated with wounds [12] [13] [14] . Cytokines whose release has been reported to be increased include TNF α , IL-1, IL-6, IL-8, IL-17, IL-23 in particular, as well as chemokines 1, 2, 3, and 16, and matrix metalloproteinases (MMP) 2 and 9 [13] [14] [15] [16] .
Even though individual case reports are usually reports of successful treatment and tend to carry little scientifi c weight, they do, however, provide evidence as to the general effectiveness of new therapies. In the meantime, data from several large cohort studies on the use of TNF α antagonists has become available, which, however, only includes cases of PG associated with chronic infl ammatory bowel disease (IBD) [ 17, 18 ] . In a study involving 60 patients with IBD and PG, Agarwal and Andrews were able to show a response to treatment in 92 % (33/36) and complete remission in one-half of the patients after just one infusion [ 17 ] . Argüelles-Arias et al. studied a similarly large patient group; here, 22 of 24 individuals experienced complete remission with infl iximab [ 18 ] . In another study by Regueiro et al. published in 2003, 13 patients saw complete recovery, 23 % of whom (3/13) already after induction therapy [ 19 ] . The randomized controlled trial by Brooklyn et al. of patients with idiopathic and IBD-associated PG treated with infl iximab demonstrated a remission rate of 69 % at week 4 and 6 (20/29), with 21 % (6/29) experiencing complete remission [ 16 ] ; the length of the observation period (six weeks) was relatively short, though [ 16 ] .
The only analysis of idiopathic and IBD-associated PG was published by our working group. Of a total of 121 patients, infl iximab was used in 12 cases, of whom 10 (83 %. 10/12) showed a good initial response with a good side effect profi le (0 %, 0/12); infl iximab therapy was discontinued in two cases due to insuffi cient effectiveness [ 11 ] .
Likewise, intravenous immunoglobulins (IVIGs) have been reported to be a safe alternative for complicated cases [20] [21] [22] [23] , one important reason being that IVIGs do not increase a patient's susceptibility to infections. Thus, the various cohort analyses of IBD-associated PG and the randomized controlled trial by Brooklyn et al. suggest the effectiveness of TNF α antagonists for this indication. There is currently no data from larger cohorts with idiopathic PG on the use of biologics and IVIGs, especially over a prolonged observation period. Against this backdrop, the objective of the present study was to analyze the treatment outcome of patients with PG treated with biologics and IVIGs and to review the effectiveness and safety of these regimens.
Material and methods

Patients
The objective of this retrospective study was to analyze the safety, effectiveness and tolerability of biologics and IVIGs in the treatment of PG. The study was conducted at two university-affi liated wound clinics, the Comprehensive Wound Center of Hamburg-Eppendorf University Medical Center and the Department of Dermatology of Essen University Medical Center. Included were patients with PG who had been treated at either medical center during the period from 2005-2015. Inclusion criteria were: 1) a diagnosis of PG (confi rmed by a dermatologist) based on the diagnostic criteria proposed by the Mayo Clinic [ 24 ] and 2) treatment with at least one biologic or IVIGs during the observation period (irrespective of the duration of treatment). The Ethics Committee of Hamburg-Eppendorf Medical Center provided ethics counseling.
Data collection
Data collection was carried out retrospectively in 2015, using patient records and a structured questionnaire. It included sociodemographic patient data, comorbidities, treatments and disease courses and was conducted by a PhD candidate.
Outcome parameters
Two different levels were distinguished in the outcome analysis: treatment outcome depending on the medication used and patient outcome. We therefore compared both patient outcomes as well as the responses to the various systemic agents ( Table 1 ). The criteria defi ned as outcome parameters with respect to the assessment of wound healing were as follows: complete remission (100 % wound closure) and improvement without complete remission (50-99 % wound closure or "clinical response" based on the physician's assessment). Other subsequent outcomes were assigned to the category "ineffectiveness".
Statistical analysis
The data collected were reported as mean values, standard deviation, minimum and maximum values or as absolute and relative frequencies, depending on the type of data. The ratio between the overall wound area and its initial size was used to determine the relative reduction in wound size. The H test (non-parametric test method) was used to compare continuous data between the various groups of drugs due to non-normal data distribution. The statistical analysis was performed using SPSS 23 for Windows (IBM Corporation, Armonk, NY, USA). All therapeutic options documented were included in the analysis, even if there was incomplete observation data. In this regard, missing data were not substituted.
Results
Sociodemographic data
Overall, 52 patients (mean age 58.4 years; 61.5 % (32/52) female) were included in the study. The wounds were predominantly located on the lower legs (71.2 %; 37/52), with a mean size of 53.2 cm² (Table 2 ) . A total of 75 wound episodes in 52 patients were analyzed as some patients experienced recurrence of a previously healed PG lesion at the same or a different site.
Comorbidities
Roughly one-half (51.9 %; 27/52) of the patients had one of the comorbidities typically associated with PG: 21.2 % (11/52) had diabetes; 9.6 % (5/52) rheumatoid arthritis; 3.8 % (2/52) other autoimmune disorders; 15,4 % (8/52) chronic infl ammatory bowel disease; and 19.2 % (10/52) a malignancy. A large number of patients exhibited features of metabolic syndrome and cardiovascular disease: 63.7 % (35/52) had anemia, 51.9 % (27/52) arterial hypertension, 25.0 % (13/52) chronic kidney disease, 13.5 % (7/52) heart failure and 15.4 % (8/52) hepatic disease. In addition, peripheral artery disease was present in 15.4 % (8/52) and chronic venous insuffi ciency in 19.2 % (10/52) of the patients. 
Use of biologics and IVIGs
Prior to the initiation of biologic or IVIG therapy, patients had received a mean of 2.6 (SD 1.6; minimum 0; maximum 7) and 4.4 (SD 2,8; minimum 1; maximum 8) previous treatments, respectively. At 82 % (68/83), TNF α antagonists were the most commonly used biologic agents (83 therapeutic attempts overall). Sixty-fi ve percent (29/52) of all patients received infl iximab (INF), 50 % (26/52) adalimumab (ADA), and 12 % (6/52) etanercept (ETA). Ustekinumab (UST) was used in 15 % (8/52) of the patients; anakinra (ANA) in 8 % (4/52). Tocilizumab and secukinumab were given to one patient (2 %; 1/52) each. IVIGs were administered in a quarter of all patients (25 %; 13/52) and 15 times overall. With INF, ADA, ETA and UST, the dosing regimen was the same as for psoriasis [ 25 ] . IVIGs were given at a dose of 2 g/kg over the course of four days every four weeks [ 21 ] . Given that this treatment constituted off-label use, it required the Figure 1 ). The highest rates of complete remission were documented for UST at 44.4 % (4/9); CSs at 38.5 % (20/78); INF at 33.3 % (11/33); and ADA at 25 % (7/28).
Reductions in wound size
Considering all medications, the mean reduction in wound size was 10. (Table 3 ) .
Combination therapies
The majority of systemic agents were initially combined with CSs. Eighty-fi ve percent (57/98) of all successful therapeutic attempts were made in conjunction with CSs. The mean initial dose was 51.4 mg (SD 36.5) of prednisolone equivalent. The mean maintenance dose for CSs was 16.7 mg (SD 21.9); in this context, there was no signifi cant difference between biologics, IVIGs and conventional immunosuppressants (p = 0.096). On average, CSs were given for 12.3 (SD 22.0) months.
Treatment duration
Overall, 24 patients were still being treated at the end of the observation period. Consideration all medications, mean treatment duration was 12.1 months (SD 21.1). While the mean duration of treatment relating to a given group of drugs varied between two and 83 months, there was no signifi cant difference between biologics, IVIGs and conventional immunosuppressants (p = 0.543).
Subgroup analysis of cases with complete remission on CSs
Overall, 56.7 % (17/30) of cases showing complete remission on CSs were achieved in combination with another immunosuppressant; 27 % (8/30) were achieved as monotherapy. Previous complete remission on a different drug was documented for 36.7 % (11/30) of therapeutic attempts; hence, these cases related to recurrences. In 20 % (6/30) of therapeutic attempts, concomitant or prior treatment had been carried out that had brought about clinical improvement and had been discontinued due to successful treatment (Table 4 ) .
Therapeutic safety
The rate of documented, relevant adverse events that led to discontinuation of a given drug averaged 18.5 % (15/81) for biologics and 20 % for IVIGs (3/15). The highest rate of adverse events per therapeutic attempt occurred with CSA (40 %, 14/35), followed by CYC (38 %, 3/8) and AZA (32 %, 8/25). On CSs, adverse events were documented merely in 6.4 % of the cases (5/48) ( Table 5 ). Four patients developed sepsis (one case each on CYC, ETA, CSs and IVIGs).
Discussion
Treatment of PG poses a challenge, a fact that has been confi rmed by previous studies [ 10, 11 ] . A prospective comparison of the standard treatments -CSs and CSA -demonstrated adverse effects in two-thirds of patients and complete remission in just under 50 % after six months [ 10 ] . Our own retrospective analysis of 121 patients revealed complete remission in only 26 % of patients on CSs and in 47 % on CSA [ 11 ] . In addition, the widespread use of other immunosuppressants, such as AZA or MMF, and the increasing use of biologics highlights the fact that the therapeutic options recommended are frequently not suffi ciently safe or effective [ 4, 6, 9, 11, 17, 18, 20, 26 ] . Abbr.: INF, infliximab; ADA, adalimumab; ETA, etanercept; UST, ustekinumab; ANA, anakinra; SEC, secukinumab; TOC, tocilizumab; IVIGs, intravenous immunoglobulins; CSs, corticosteroids; CSA, cyclosporine A; AZA, azathioprine; MTX, methotrexate; MMF, mycophenolate mofetil; CYC, cyclophosphamide; FAE, fumaric acid esters; SSA, sulfasalazine;SD, standard deviation. Given that biologics and IVIGs have not been approved for this indication, they are usually given only once the recommended agents -CSA and CSs -have failed to produce clinical improvement or if they are contraindicated. This is also refl ected in our cohort of 52 patients: 92 % received CSs and 54 % CSA, with 52 % of all patients having arterial hypertension and 25 % having chronic kidney disease. Moreover, a number of previous treatments had been carried out in most cases: 2.6 prior to biologics and 4.4 prior to IVIGs.
With respect to TNF α antagonists, ustekinumab and IVIGs, roughly two-thirds (57.1-71.4 %) of all therapeutic attempts resulted in a clinical response and/or complete remission; however, the number of cases treated with ETA and UST was quite low. By comparison, that fi gure was 48.8 % for CSs and a mere 20 % for CSA.
A comparison of the response to biologics and IVIGs with the response to standard therapeutic agents -CSs and CSA -is only possible to a limited extent, given that only patients who received biologics or IVIGs were included in the study. However, with the exception of three cases, these treatments were given only after CSA or CSs had proven to be ineffective or if there were contraindications.
While analysis of the therapeutic attempts revealed a high rate of complete remission on CSs (45 %; 30/67), the majority (56.7 % or 17/30) of these cases were combination therapies. A mere 20 % (6/30) of PG lesions healed without any concomitant or prior treatment with another immunosuppressant. This large number of successful corticosteroid therapies can be explained by common treatment practices with respect to PG. In general, a low maintenance dose of CSs is administered in combination with another immunosuppressant. Once it is possible to discontinue the latter, the CS maintenance dose is then continued until wound closure. In most cases, recurrences too are initially treated with CS pulse therapy. As the diagnosis is already known, treatment can be commenced at a very early stage. This is likely the reason why a disease fl are can be countered with CSs alone and why no other long-term medication is required.
Our data suggests that biologics -TNF α antagonists in particular -and IVIGs are both effective and safe therapeutic options; highlighted by the fact that the patients included in our study represented complicated cases. This is refl ected by the number of treatments (275 therapeutic attempts; on average, 2.6 previous treatments prior to biologics and 4.4 prior to IVIGs), the (long) mean observation period (67.4 months, SD 39.8) and the mean treatment duration per medication (11.0 months).
In patients with PG, IVIGs are given as rescue medication, especially in individuals at increased risk of infection as well as those with rapid disease progression or with a malignancy [ 20, 21, 23 ] . Given that the administration of IVIGs is time consuming and associated with high costs, they are usually given only in the early stages of treatment and frequently replaced by an alternative oral medication once clinical improvement has set in. Thus, the rate of complete remission by itself does not adequately refl ect their therapeutic role. In this context, 15 therapeutic attempts resulted in three cases of complete remission (20.0 %) and seven cases of clinical [ 19, [27] [28] [29] and on long-term concomitant treatment [ 30 ] . Our patients initially received, on average, 51.4 mg of prednisolone equivalent; most patients were subsequently also given concomitant CS treatment (mean: 16.7 mg), irrespective of the other systemic agent used.
It must be noted, though, that the risk of developing sepsis is signifi cantly higher for patients receiving combination therapy with CSs, at least for individuals with IBD [ 31, 32 ] . Further data is required to assess whether the combination of CSs with biologics or IVIGs in the management of this complicated disorder is a suffi ciently safe option, especially in terms of potential infections.
The rate of adverse events per therapeutic attempt was higher with all conventional immunosuppressants, except for CSs and MTX (15.4 %), than with biologics or IVIGs. The rate was 18.2 % for INF; 17.9 % for ADA; and 20 % for IVIGs. Given that biologics and IVIGs are generally used only once adverse effects have occurred, if there are contraindications, or if treatment with conventional immunosuppressants has failed, it is impossible to rule out any bias with respect to the rate of adverse effects. However, the fact that the rate of adverse effects, especially for CSA (40 %), is comparable to earlier publications suggests that this concern is unwarranted [ 10, 11 ] .
The most common adverse effects associated with the use of biologics were infections and allergic reactions. The rate of adverse effects associated with CSs is likely to be signifi cantly underreported, given that physicians do not specifi cally enough ask their patients about common adverse effects, such as elevated glucose levels or Cushing's symptoms, in everyday clinical practice; overall, such events are therefore documented quite rarely.
The present study of 52 patients is the largest to date on the use of biologics and IVIGs in the treatment of PG, including cases not associated with IBD. Although the retrospective non-randomized design constitutes a methodological limitation and confounding factors cannot be ruled out, the large number of cases and the long observation period suggest that the data obtained provides a realistic insight into current treatment practices for PG. In order to be able to compare the effectiveness of the various therapeutic options as well as possible, we not only assessed complete remission rates but we also systematically examined clinical response rates after twelve weeks.
Conclusions
Although the number of patients and the retrospective design of the present study suggest that the data obtained is not suffi ciently conclusive to make defi nitive treatment recommendations, our fi ndings do underscore the need for safe and effective treatment alternatives to CSs and CSA. Given the high frequency of severe comorbidities and the good tolerability and safety profi le of biologics, especially TNF α antagonists, their use should be considered early on in the management of PG. IVIGs are useful in the treatment of patients with malignancies as well as severely ill individuals. Unfortunately, there is currently insuffi cient prospective data that would allow for general treatment recommendations.
